Daiichi wins $400M award for being deceived about Ranbaxy's problems

Indian money
Daiichi Sankyo logo

Daiichi Sankyo claimed it had been deceived when its venture into Indian generic drug manufacturing turned into a regulatory maelstrom that eventually led it to unload Ranbaxy Laboratories at a loss. Now an international arbitration court has agreed.

The Singapore Court of Arbitration has decided the Japanese drugmaker should be awarded $400 million from Malvinder Mohan Singh and Shivinder Mohan Singh, the two lead Ranbaxy investors who sold their stake in the company to Daiichi for $2.4 billion in 2008, the Economic Times reports. It paid about $4.6 billion to get controlling interest.

Daiichi filed the arbitration action against the brothers in 2013, after Ranbaxy pleaded to 7 felonies charges related to manufacturing poor quality drugs and it and Daiichi agreed to a $500 million settlement with the U.S. authorities to settle litigation.

By that point the company had had two plants banned by the FDA from shipping products to the U.S. and fallen under the provisions of a court-ordered consent decree requiring it to have outside auditors track its progress. The actions had begun after authorities were tipped off by a whistleblower that Ranbaxy, among other things, had faked test data on drug tests, showing that products met FDA standards when they did not.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

When problems persisted and the FDA banned two more Ranbaxy plants, Daiichi decided it had had enough and agreed to sell the company at a loss to Sun Pharmaceutical in an all stock deal valued at about $4 billion. Sun has pledged to fix Ranbaxy’s quality issues.

- read the Economic Times story

Related Articles: 
Daiichi Sankyo says it was burned in Ranbaxy buyout 
Daiichi Sankyo sells off Ranbaxy's problems to Sun Pharma

Suggested Articles

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.

Pfizer is ponying up $500 million on top of $100 million already committed to a gene therapy manufacturing facility in North Carolina.